
Darzalex-Rd Combination Can Enhance Multiple Myeloma Treatment
FREMONT, CA –Recently a group of researchers from the United States, France, and Belgium conducted a Phase III MAIA trial. It showed that the risk of disease progression or death was 44 percent lower in the case of Darzalex-Rd when compared to Rd alone.
The Darzalex-Rd is the combination of Darzalex (daratumumab) of Janssen with Revlimid (lenalidomide) and dexamethasone (Rd) of Celgene. According to the study, the combination treatment increases progression-free survival (PFS) of recent multiple myeloma patients who are ineligible for autologous stem cell transplants.
Post 28 months of treatment, 240 patients either experienced disease progression or died. 26.4 percent of them were in the triple combination group, while 38.8 percent in the Rd group. According to the researchers, the overall response rate for Darzalex-Rd was 92.9 percent, whereas it was 81.3 percent for Rd. The incorporation of Darzalex in the combination treatment increased the response from 24.9 percent to 47.6 percent. The study also showed that 24.2 percent of the groups undergoing Darzalex-Rd treatment witnessed results well below the threshold of minimal residual disease. On the other hand, only 7.3 percent of the people in the Rd group saw these results.
According to the lead author and investigator of the study, the scientific evidence facilitated by the study showed the effectiveness of using Darzalex in combination with the standard care regimen. The multiple myeloma can turn more complicated after every relapse; hence, it is vital to undergo optimal upfront therapy. The results of the MAIA study show that the Darzalex-Rd combination therapy is especially useful for patients with multiple myeloma who are ineligible for transplant after diagnosis. Darzalex is the only CD38-directed antibody which is allowed for treating multiple myeloma. Also, patients who have undergone at least one line of prior therapy are allowed to be treated with the Darzalex-Rd combination.
The outcomes of the MAIA study carries out by the researchers exhibit a consistent and effective treatment when incorporating Darzalex in standard backbone regimens such as lenalidomide and dexamethasone when treating patients with multiple myeloma who are ineligible for transplants. The researchers have sent applications to global health authorities endorsing the MAIA results and are looking forward to collaborating with regulators to aid in the treatment of multiple myeloma patients.
Check Out : CIOReview | Medium
Featured Vendors
Tenthpin: The Trusted Advisor for Data-Driven Patient- Centric Value Chain Management in Life Sciences
Process Stream: Into the Depths: How Process Stream Leverages Experience and Embedded Research to Transform Businesses from the Inside Out
Indegene: Leveraging Technology to Drive Growth and Productivity Investing In Innovation In Operations, Analytics and Clinical Technology
MMIS: Global Compliance Platform Streamlines Processes and Delivers Business Intelligence Enterprise-Wide
Acceliant: Leading with Innovation, Facilitating Collaboration, Standardization and Productivity in Clinical Trial Management
Saama Technologies: New Fluid Analytics Engine from Saama Cost-Effectively and Rapidly Resolves Complex Data Analytics Challenges for Life Sciences
Iris Interactive Corporation: Boosting Collaboration and Decision Making Processes to Bring Products
Techsol Corporation: Offering Domain Rich, Regulatory Compliant, Accelerated and Cloud Enabled Techn
Solea Software Solutions: Offering Business Intelligence, Analytics, and Portal Services for Flouris
Xybion Corporation: Providing Interconnected Technology Enabled Solutions for Life Sciences, and oth
EDITOR'S PICK
Essential Technology Elements Necessary To Enable...
By Leni Kaufman, VP & CIO, Newport News Shipbuilding
Comparative Data Among Physician Peers
By George Evans, CIO, Singing River Health System
Monitoring Technologies Without Human Intervention
By John Kamin, EVP and CIO, Old National Bancorp
Unlocking the Value of Connected Cars
By Elliot Garbus, VP-IoT Solutions Group & GM-Automotive...
Digital Innovation Giving Rise to New Capabilities
By Gregory Morrison, SVP & CIO, Cox Enterprises
Staying Connected to Organizational Priorities is Vital...
By Alberto Ruocco, CIO, American Electric Power
Comprehensible Distribution of Training and Information...
By Sam Lamonica, CIO & VP Information Systems, Rosendin...
The Current Focus is On Comprehensive Solutions
By Sergey Cherkasov, CIO, PhosAgro
Big Data Analytics and Its Impact on the Supply Chain
By Pascal Becotte, MD-Global Supply Chain Practice for the...
Technology's Impact on Field Services
By Stephen Caulfield, Executive Director, Global Field...
Carmax, the Automobile Business with IT at the Core
By Shamim Mohammad, SVP & CIO, CarMax
The CIO's role in rethinking the scope of EPM for...
By Ronald Seymore, Managing Director, Enterprise Performance...
Driving Insurance Agent Productivity with Mobile and Big...
By Brad Bodell, SVP and CIO, CNO Financial Group, Inc.
Transformative Impact On The IT Landscape
By Jim Whitehurst, CEO, Red Hat
Get Ready for an IT Renaissance: Brought to You by Big...
By Clark Golestani, EVP and CIO, Merck
Four Initiatives Driving ECM Innovation
By Scott Craig, Vice President of Product Marketing, Lexmark...
Technology to Leverage and Enable
By Dave Kipe, SVP, Global Operations, Scholastic Inc.
By Meerah Rajavel, CIO, Forcepoint
AI is the New UI-AI + UX + DesignOps
By Amit Bahree, Executive, Global Technology and Innovation,...
Evolving Role of the CIO - Enabling Business Execution...
By Greg Tacchetti, CIO, State Auto Insurance
Read Also
